{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T13:42:08Z","timestamp":1791726128076,"version":"4.3.4"},"reference-count":70,"publisher":"Oxford University Press (OUP)","issue":"Supplement_3","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,10,31]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>After almost 30 years of relative stagnation, research over the past decade has led to remarkable advances in the treatment of both drug-susceptible (DS) and drug-resistant (DR) tuberculosis (TB) disease in children and adolescents. Compared with the previous standard therapy of at least 6 months, 2 new regimens lasting for only 4 months for the treatment of DS-TB have been studied and are recommended by the World Health Organization (WHO), along with a shortened 6-month regimen for treatment of DS-TB meningitis. In addition, the 18- to 24-month regimens previously used for DR-TB that included painful injectable drugs with high rates of adverse effects have been replaced with shorter, safer all-oral regimens. Advances that have improved treatment include development of new TB drugs (bedaquiline, delamanid, pretomanid), reapplication of older TB drugs (rifampicin and rifapentine), and repurposing of other drugs (clofazimine and linezolid). The development of child-friendly formulations for many of these drugs has further enhanced the ability to safely and effectively treat DS- and DR-TB in children and adolescents. The characteristics and use of these drugs, regimens, and formulations are reviewed.<\/jats:p>","DOI":"10.1093\/jpids\/piac047","type":"journal-article","created":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T16:21:47Z","timestamp":1661358107000},"page":"S101-S109","source":"Crossref","is-referenced-by-count":13,"title":["New Drugs and Regimens for Tuberculosis Disease Treatment in Children and Adolescents"],"prefix":"10.1093","volume":"11","author":[{"given":"Anthony J","family":"Garcia-Prats","sequence":"first","affiliation":[{"name":"Department of Pediatrics, University of Wisconsin School of Medicine and Public Health , Madison, Wisconsin , USA"},{"name":"Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Stellenbosch University , Cape Town , South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey R","family":"Starke","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Baylor College of Medicine , Houston, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Waning","sequence":"additional","affiliation":[{"name":"Global Drug Facility, Stop TB Partnership , Geneva , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Kaiser","sequence":"additional","affiliation":[{"name":"Global Drug Facility, Stop TB Partnership , Geneva , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A","family":"Seddon","sequence":"additional","affiliation":[{"name":"Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Stellenbosch University , Cape Town , South Africa"},{"name":"Department of Infectious Diseases, Imperial College London , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,10,31]]},"reference":[{"key":"2022103111080042300_CIT0001","volume-title":"Global Tuberculosis Report 2021","author":"World Health Organization","year":"2021"},{"key":"2022103111080042300_CIT0002","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/S1473-3099(16)30132-3","article-title":"Global burden of drug-resistant tuberculosis in children: a mathematical modelling study","volume":"16","author":"Dodd","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2022103111080042300_CIT0003","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/S0140-6736(14)60195-1","article-title":"Incidence of multidrug-resistant tuberculosis disease in children: systematic review and global estimates","volume":"383","author":"Jenkins","year":"2014","journal-title":"Lancet"},{"key":"2022103111080042300_CIT0004","author":"Stop TB Partnership"},{"key":"2022103111080042300_CIT0005","doi-asserted-by":"crossref","first-page":"e1002591","DOI":"10.1371\/journal.pmed.1002591","article-title":"Treatment and outcomes in children with multidrug-resistant tuberculosis: a systematic review and individual patient data meta-analysis","volume":"15","author":"Harausz","year":"2018","journal-title":"PLoS Med"},{"key":"2022103111080042300_CIT0006","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1473-3099(16)30474-1","article-title":"Mortality in children diagnosed with tuberculosis: a systematic review and meta-analysis","volume":"17","author":"Jenkins","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2022103111080042300_CIT0007","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.3201\/eid2612.202245","article-title":"Tuberculosis among children and adolescents at HIV treatment centers in sub-Saharan Africa","volume":"26","author":"Mandalakas","year":"2020","journal-title":"Emerg Infect Dis"},{"key":"2022103111080042300_CIT0008","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jinf.2012.09.002","article-title":"Hearing loss in children treated for multidrug-resistant tuberculosis","volume":"66","author":"Seddon","year":"2013","journal-title":"J Infect"},{"key":"2022103111080042300_CIT0009","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1183\/09031936.00187711","article-title":"Childhood tuberculosis: progress requires an advocacy strategy now","volume":"40","author":"Sandgren","year":"2012","journal-title":"Eur Respir J"},{"key":"2022103111080042300_CIT0010","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.curtheres.2018.12.001","article-title":"Pediatric drug development: challenges and opportunities","volume":"90","author":"Spadoni","year":"2019","journal-title":"Curr Ther Res"},{"key":"2022103111080042300_CIT0011","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.clinthera.2016.01.012","article-title":"Improvement of pediatric drug development: regulatory and practical frameworks","volume":"38","author":"Tsukamoto","year":"2016","journal-title":"Clin Ther"},{"key":"2022103111080042300_CIT0012","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1126\/science.1106753","article-title":"A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis","volume":"307","author":"Andries","year":"2005","journal-title":"Science"},{"key":"2022103111080042300_CIT0013","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1093\/jac\/dku171","article-title":"Bedaquiline: a review of human pharmacokinetics and drug-drug interactions","volume":"69","author":"van Heeswijk","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2022103111080042300_CIT0014","volume-title":"Bedaquiline FDA Package Insert: Sirturo (Bedaquiline) [Package Insert]","year":"2019"},{"key":"2022103111080042300_CIT0015","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1056\/NEJMoa1313865","article-title":"Multidrug-resistant tuberculosis and culture conversion with bedaquiline","volume":"371","author":"Diacon","year":"2014","journal-title":"N Engl J Med"},{"key":"2022103111080042300_CIT0016","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S2213-2600(18)30235-2","article-title":"Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study","volume":"6","author":"Schnippel","year":"2018","journal-title":"Lancet Respir Med"},{"key":"2022103111080042300_CIT0017","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0140-6736(18)31644-1","article-title":"Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis","volume":"392","author":"Ahmad","year":"2018","journal-title":"Lancet"},{"key":"2022103111080042300_CIT0018","author":"World Health Organization"},{"key":"2022103111080042300_CIT0019","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa1901814","article-title":"Treatment of highly drug-resistant pulmonary tuberculosis","volume":"382","author":"Conradie","year":"2020","journal-title":"N Engl J Med"},{"key":"2022103111080042300_CIT0020","author":"McKenna"},{"key":"2022103111080042300_CIT0021","author":"Johnson & Johnson (Press Release)","year":"2020"},{"key":"2022103111080042300_CIT0022","doi-asserted-by":"crossref","first-page":"716","DOI":"10.5588\/ijtld.21.0022","article-title":"Bedaquiline for multidrug-resistant TB in paediatric patients","volume":"25","author":"Moodliar","year":"2021","journal-title":"Int J Tuberc Lung Dis"},{"key":"2022103111080042300_CIT0023","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3390\/pathogens11020128","article-title":"Pediatric tuberculosis research and development: progress, priorities and funding opportunities","volume":"11","author":"McKenna","year":"2022","journal-title":"Pathogens"},{"key":"2022103111080042300_CIT0024","author":"World Health Organization","year":"2019"},{"key":"2022103111080042300_CIT0025","author":"World Health Organization","year":"2021"},{"key":"2022103111080042300_CIT0026","doi-asserted-by":"crossref","first-page":"e00463","DOI":"10.1128\/AAC.00463-19","article-title":"Daily dosing for bedaquiline in patients with tuberculosis","volume":"63","author":"Salinger","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2022103111080042300_CIT0027","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.tube.2018.04.008","article-title":"Delamanid: from discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB)","volume":"111","author":"Liu","year":"2018","journal-title":"Tuberculosis"},{"key":"2022103111080042300_CIT0028","author":"European Medicines Agency"},{"key":"2022103111080042300_CIT0029","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S2213-2600(18)30426-0","article-title":"Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial","volume":"7","author":"von Groote-Bidlingmaier","year":"2019","journal-title":"Lancet Respir Med"},{"key":"2022103111080042300_CIT0030","doi-asserted-by":"crossref","first-page":"e0160821","DOI":"10.1128\/AAC.01608-21","article-title":"Population pharmacokinetic and concentration-QTc analysis of delamanid in pediatric participants with multidrug-resistant tuberculosis","volume":"66","author":"Sasaki","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2022103111080042300_CIT0031","author":"World Health Organization","year":"2016"},{"key":"2022103111080042300_CIT0032"},{"key":"2022103111080042300_CIT0033"},{"key":"2022103111080042300_CIT0034","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1093\/jac\/dkw426","article-title":"Mechanisms of action and therapeutic efficacies of the lipophilic antimycobacterial agents clofazimine and bedaquiline","volume":"72","author":"Cholo","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2022103111080042300_CIT0035","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1080\/14740338.2016.1216544","article-title":"Adverse effects of oral second-line antituberculosis drugs in children","volume":"15","author":"Schaaf","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"2022103111080042300_CIT0036","doi-asserted-by":"crossref","first-page":"e0268720","DOI":"10.1128\/AAC.02687-20","article-title":"Effect of clofazimine concentration on QT prolongation in patients treated for tuberculosis","volume":"65","author":"Abdelwahab","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2022103111080042300_CIT0037","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1164\/rccm.201001-0077OC","article-title":"Highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis","volume":"182","author":"Van Deun","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"2022103111080042300_CIT0038","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1811867","article-title":"A trial of a shorter regimen for rifampin-resistant tuberculosis","volume":"380","author":"Nunn","year":"2019","journal-title":"N Engl J Med"},{"key":"2022103111080042300_CIT0039","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.jcf.2021.08.010","article-title":"Administration and monitoring of clofazimine for NTM infections in children with and without cystic fibrosis","volume":"21","author":"Cameron","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2022103111080042300_CIT0040","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1056\/NEJMoa1201964","article-title":"Linezolid for treatment of chronic extensively drug-resistant tuberculosis","volume":"367","author":"Lee","year":"2012","journal-title":"N Engl J Med"},{"key":"2022103111080042300_CIT0041","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1183\/09031936.00022912","article-title":"Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis","volume":"40","author":"Sotgiu","year":"2012","journal-title":"Eur Respir J"},{"key":"2022103111080042300_CIT0042","article-title":"High rate of successful outcomes treating highly resistant TB in the ZeNix study of pretomanid, bedaquiline and alternative doses and durations of linezolid.","author":"Conradie"},{"key":"2022103111080042300_CIT0043","doi-asserted-by":"crossref","first-page":"e1002789","DOI":"10.1371\/journal.pmed.1002789","article-title":"Pharmacokinetics, optimal dosing, and safety of linezolid in children with multidrug-resistant tuberculosis: combined data from two prospective observational studies","volume":"16","author":"Garcia-Prats","year":"2019","journal-title":"PLoS Med"},{"key":"2022103111080042300_CIT0044","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1093\/cid\/cir184","article-title":"Why do we use 600 mg of rifampicin in tuberculosis treatment?","volume":"52","author":"van Ingen","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2022103111080042300_CIT0045","doi-asserted-by":"crossref","first-page":"2000955","DOI":"10.1183\/13993003.00955-2020","article-title":"Increased bactericidal activity but dose-limiting intolerability at 50 mg\u00b7kg\u22121 rifampicin","volume":"58","author":"Te Brake","year":"2021","journal-title":"Eur Respir J"},{"key":"2022103111080042300_CIT0046","doi-asserted-by":"crossref","first-page":"3237","DOI":"10.1093\/jac\/dkab336","article-title":"Pharmacokinetics and safety of high-dose rifampicin in children with TB: the Opti-Rif trial","volume":"76","author":"Garcia-Prats","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2022103111080042300_CIT0047","volume-title":"Priftin (Rifapentine) [Package Insert]","year":"2014"},{"key":"2022103111080042300_CIT0048","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","article-title":"Three months of rifapentine and isoniazid for latent tuberculosis infection","volume":"365","author":"Sterling","year":"2011","journal-title":"N Engl J Med"},{"key":"2022103111080042300_CIT0049","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa1806808","article-title":"One month of rifapentine plus isoniazid to prevent HIV-related tuberculosis","volume":"380","author":"Swindells","year":"2019","journal-title":"N Engl J Med"},{"key":"2022103111080042300_CIT0050","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1056\/NEJMoa2033400","article-title":"Four-month rifapentine regimens with or without moxifloxacin for tuberculosis","volume":"384","author":"Dorman","year":"2021","journal-title":"N Engl J Med"},{"key":"2022103111080042300_CIT0051","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1093\/jpids\/pit077","article-title":"Rifapentine pharmacokinetics and tolerability in children and adults treated once weekly with rifapentine and isoniazid for latent tuberculosis infection","volume":"3","author":"Weiner","year":"2014","journal-title":"J Pediatr Infect Dis Soc"},{"key":"2022103111080042300_CIT0052","author":"Stop TB Partnership","year":"2022"},{"key":"2022103111080042300_CIT0053","author":"WHO"},{"key":"2022103111080042300_CIT0054","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1186\/s13063-018-2608-5","article-title":"Shorter treatment for minimal tuberculosis (TB) in children (SHINE): a study protocol for a randomised controlled trial","volume":"19","author":"Chabala","year":"2018","journal-title":"Trials"},{"key":"2022103111080042300_CIT0055","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa2104535","article-title":"Shorter treatment for nonsevere tuberculosis in African and Indian children","volume":"386","author":"Tukova","year":"2022","journal-title":"N Engl J Med"},{"key":"2022103111080042300_CIT0056","author":"World Health Organization","year":"2021"},{"key":"2022103111080042300_CIT0057","doi-asserted-by":"crossref","first-page":"285","DOI":"10.15585\/mmwr.mm7108a1","article-title":"Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis \u2014 United States, 2022.","volume":"71","author":"Carr","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2022103111080042300_CIT0058","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.3390\/pathogens11010038","article-title":"Tuberculous meningitis in children: reducing the burden of death and disability","volume":"11","author":"Huynh","year":"2021","journal-title":"Pathogens"},{"key":"2022103111080042300_CIT0059"},{"key":"2022103111080042300_CIT0060","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.5588\/ijtld.18.0786","article-title":"Challenges in conducting trials for pediatric tuberculous meningitis: lessons from the field","volume":"23","author":"Padadkar","year":"2019","journal-title":"Int J Tuberc Lung Dis"},{"key":"2022103111080042300_CIT0061","first-page":"ciac208","article-title":"TBM-KIDS Study Team. Randomized clinical trial of high dose rifampicin with or without levofloxacin versus standard of care for paediatric tuberculous meningitis: The TBM-KIDS trial.","author":"Aradkar","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2022103111080042300_CIT0062"},{"key":"2022103111080042300_CIT0063","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/cpt.202","article-title":"Pediatric tuberculous meningitis: model-based approach to determining optimal doses of the anti-tuberculosis drugs rifampin and levofloxacin for children","volume":"98","author":"Savic","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"2022103111080042300_CIT0064","author":"World Health Organization","year":"2014"},{"key":"2022103111080042300_CIT0065","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1164\/rccm.201001-0077OC","article-title":"Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis","volume":"182","author":"Van Deun","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"2022103111080042300_CIT0066","author":"World Health Organization","year":"2016"},{"key":"2022103111080042300_CIT0067","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.5588\/ijtld.20.0330","article-title":"Clinical perspectives on treatment of rifampicin-resistant\/multidrug-resistant TB","volume":"24","author":"Cox","year":"2020","journal-title":"Int J Tuberc Lung Dis"},{"key":"2022103111080042300_CIT0068"},{"key":"2022103111080042300_CIT0069","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nri3813","article-title":"Advancing host-directed therapy for tuberculosis","volume":"15","author":"Wallace","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"2022103111080042300_CIT0070","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/S2213-2600(20)30448-3","article-title":"Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial","volume":"9","author":"Wallace","year":"2021","journal-title":"Lancet Respir Med"}],"container-title":["Journal of the Pediatric Infectious Diseases Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jpids\/article-pdf\/11\/Supplement_3\/S101\/46655587\/piac047.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpids\/article-pdf\/11\/Supplement_3\/S101\/46655587\/piac047.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T11:08:35Z","timestamp":1667214515000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpids\/article\/11\/Supplement_3\/S101\/6775661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,1]]},"references-count":70,"journal-issue":{"issue":"Supplement_3","published-online":{"date-parts":[[2022,10,31]]},"published-print":{"date-parts":[[2022,10,31]]}},"URL":"https:\/\/doi.org\/10.1093\/jpids\/piac047","relation":{},"ISSN":["2048-7207"],"issn-type":[{"value":"2048-7207","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,10,1]]},"published":{"date-parts":[[2022,10,1]]}}}